PARP-ARPI Combo Sets New Standard for Metastatic Hormone-Sensitive Prostate Cancer

(MedPage Today) — CHICAGO — Men with homologous recombination repair (HRR)-deficient, metastatic, castration-sensitive prostate cancer (mCSPC) lived significantly longer without disease progression when they received a PARP inhibitor in addition…

Source link : https://www.medpagetoday.com/meetingcoverage/asco/115861

Author :

Publish date : 2025-06-03 12:00:00

Copyright for syndicated content belongs to the linked Source.

M	T	W	T	F	S	S
				1	2	3
4	5	6	7	8	9	10
11	12	13	14	15	16	17
18	19	20	21	22	23	24
25	26	27	28	29	30	31

PARP-ARPI Combo Sets New Standard for Metastatic Hormone-Sensitive Prostate Cancer

Dex Linked to Lower Delirium Incidence After Cardiac Surgery

Struggling for German Licence? Five Insider Tips

Related Posts

When to Refer Pediatric Allergic Rhinitis From Primary Care

Fourth Person Dies in Legionnaires’ Disease Outbreak: Here’s What to Know

President Trump Wants to Undo EPA’s Ability to Protect Our Climate and Air

Oldest fast radio burst ever seen sheds light on early star formation

MAHA Report Leaked; ACIP Member’s ‘Violent Rhetoric’; Cholera Outbreak

A Viable Option for Severe Ulcerative Colitis

When to Refer Pediatric Allergic Rhinitis From Primary Care

Fourth Person Dies in Legionnaires’ Disease Outbreak: Here’s What to Know

President Trump Wants to Undo EPA’s Ability to Protect Our Climate and Air

Oldest fast radio burst ever seen sheds light on early star formation

MAHA Report Leaked; ACIP Member’s ‘Violent Rhetoric’; Cholera Outbreak

AI Detects Missed Interval Breast Cancer on Mammograms

We have detected a single electron with unprecedented speed

A Viable Option for Severe Ulcerative Colitis

Categories

Archives